CDC Works To Track Evidence Gaps On Pharmacogenetic Tests
This article was originally published in The Gray Sheet
Executive Summary
CMS is looking for the best ways to assess pharmacogenetic test data so it can keep its coverage policies current as new developments are made in personalized medicine
You may also be interested in...
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.